The Medical Letter on Drugs and Therapeutics
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
The FDA has approved Nuedexta (Avanir), a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Article code: 1366b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.